Hafez · Tissue & cell 2026 · Controlled animal experiment · n=48 rats

Allicin attenuates age-related cognitive and neural decline in a rat model by modulating amyloid burden and regulating BDNF/NrF2 gene expression.

Cited 1 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Animal model study with no human data.

PubMed 41205312 · doi:10.1016/j.tice.2025.103208 · record verified 2026-08-29

What was done

Forty-eight male Wistar rats were divided into six groups: young control, old control, and allicin-treated groups (20 mg/kg and 40 mg/kg for both young and old rats) administered orally for eight weeks. Assessments included neurobehavioral tests, cerebral biomarker analysis, neurotransmitter levels, BDNF and Nrf2 mRNA expression, antioxidative status, histopathological evaluations, and molecular docking analyses.

What was found

The abstract reports no exact numbers, percentages, or effect sizes. Qualitatively, aging was reported to cause cognitive decline, increased anxiety behaviors, oxidative stress, DNA damage, neuroinflammation, amyloid-beta (Aβ 1-42) accumulation, and reduced BDNF and Nrf2 expression. Allicin treatment was reported to restore neurotransmitter function, enhance antioxidant defenses, reduce inflammation and amyloid burden, and upregulate BDNF and Nrf2 gene expression.

Why it matters

This study outlines potential antioxidant and neuroprotective mechanisms of allicin in an aging rodent model, pointing to BDNF and Nrf2 regulation as possible therapeutic targets.

Limits

The findings come entirely from male rats and cannot be directly translated to human clinical outcomes. The abstract provides no quantitative data, error margins, or comparisons between the two tested dosages.

Cited by